Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An International Oncology Study Group (IOSG) Phase II protocol

American Journal of Hematology

Volumn 63, Issue 3, 2000, Pages 125-130

  Giles, Francis J ^a,f   Wickham, Nicholas R ^b   Rapoport, Bernardo L ^c   Somlo, George ^d   Lim, Stephen W ^e   Shan, Jianqin ^a   Lynott, Anne M ^a  

^a International Oncology Study Group   (United States)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c Medical Oncology Centre of Rosebank   (South Africa)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f International Oncology Study Group   (United States)

Author keywords

Adriamycin; Cyclophosphamide; Dexamethasone; Etoposide; Myeloma; Vincristine

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0033997659     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S     Document Type: Article

References (35)

1. Giles FJ. Current therapy of refractory multiple myeloma. Stem Cells (Dayton) 1995:13(Suppl 2):88-105.
2. Giles FJ. Refractory multiple myeloma: recent advances in therapy. Hematol Pathol 1995;9:121-140.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
4. Barlogie B, Vesole DH, Jagannath S. Salvage therapy for multiple myeloma: the University of Arkansas experience. Mayo Clin Proc 1994;69:787-795.
5. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-1356.
6. Adam Z, Elbl L, Vorlicek J, et al. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD). Acta Med Austriaca 1994;21:111-115.
7. Blade J, San Miguel J, Sanz-Sanz MA, et al. Treatment of melphalan-resistant multiple myeloma with vincristine. BCNU, doxorubicin, and high-dose dexamethasone (VBAD). Eur J Cancer 1992;1:57-60.
8. Browman GP, Belch A, Skillings J, et al. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol 1992;82:555-559.
9. Cook G, Sharp RA, Tansey P, Franklin IM. A Phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 1996;93:931-934.
10. Dalton WS, Crowley JJ, Salmon SS, et al. A Phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995;75:815-820.
11. Forgeson GV, Selby P, Lakhuni S, et al. Infused vincristine and adriamycin with high-dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 1988;58:469-473.
12. Gimsing P, Bjerrum OW, Brandt E, et al. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a Phase II study. The Nordic Myeloma Study Group (NMSG). Br J Haematol 1991;77:73-79.
13. Glasmacher A, Halerlach T, Gorschluter M, et al. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997;11(Suppl 5):S22-26.
14. Koskela K, Pelliniemi TT, Remes K. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymphoma 1993;10:347-351.
15. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30.
16. Mineur P, Menard JF, Le Loet X, et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 1998;103:512-517.
17. Monconduit M, Menard JF, Michaux JL, et al. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Br J Haematol 1992;80:199-204.
18. Phillips JK, Sherlaw-Johnson C, Pearce R, et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995;17:465-472.
19. Scheithauer W, Cortelezzi A, Kutzmits R, Baldini L, Ludwig H. VAD protocol for treatment of advanced refractory multiple myeloma. Blut 1987;55:145-152.
20. Sheehan T, Judge M, Parker AC. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders. Scand J Haematol 1986;37:425-428.
21. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma 1995;19:159-163.
22. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-1582.
23. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
24. Carrion JR, Garcia Arroyo FR, Salinas P. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 1995;18:44-46.
25. Moreau P, Fiere D, Bezwoda WR, et al. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997;15:660-666.
26. Troussard X, Macro M, Vie B, et al. Human recombinant granulocyte-macrophage colony stimulating factor (hrGM-CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: a pilot study. Br J Haematol 1995;89:191-195.
27. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94:659-664.
28. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-89.
29. Kars A, Celik I, Kansu E, et al. Maintenance therapy with α-interferon following first-line VAD in multiple myeloma. Eur J Haematol 1997; 59:100-104.
30. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2:882-885.
31. Ohrling M, Bjorkholm M, Osterborg A, et al. Etoposide, doxorubicin, cyclophosphamide and high-dose betamethasone (EACB) as outpatient salvage therapy for refractory multiple myeloma. Eur J Haematol 1993;51:45-49.
32. Ballester OF, Moscinski LC, Fields KK, et al. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Br J Haematol 1997;96:746-748.
33. Dimopoulos MA, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 1993;83:240-244.
34. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 1996;52:77-81.
35. Pratt G, Wiles ME, Rawstron AC, et al. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998; 16:47-55.